{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2328450"],"location":["China"],"study_start_month":["5"],"keyword":["Irinotecan","Capecitabine","XELIRI","Fluorouracil","Bevacizumab","FOLFIRI"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer","description":"This is a Phase II, multicenter，randomized, two arms, open-labeled, controlled clinical trial. This trial was conducted to evaluate the efficacy and safety of bevacizumab (Avastin) plus mXELIRI compared with bevacizumab (Avastin) plus FOLFIRI as first-line treatment in patients with metastatic colorectal cancer (mCRC).","dates":{"creation":"2018-05-15"},"accession":"2328450","cross_references":{"ClinicalTrials___gov":["NCT04247984"]}}